TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32764878
Drug: Ondansetron administered
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron administered 5 min before intrathecal injection
Study: 32764878
Drug: Ondansetron administered
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron administered 15 min before intrathecal injection
Study: 32764878
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 5 min or 15 min before intrathecal injection
Study: 32219502
Drug: Scheduled combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled combination therapy with carboplatin/paclitaxel plus oregovomab
Study: 35763763
Drug: eGFR values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR values lower than 50 ml/min/1.73 m2
Study: 35445718
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with Lucitanib
Study: 35445718
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with Lucitanib
Study: 34511515
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention (CI) including non-nutritive sucking (NNS), oral motor stimulation, and oral support
Study: 35811140
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection analgesia
Study: 32168298
Drug: IV tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tirofiban infusion
Study: 33848675
Drug: Hydroxychloroquine (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (not specified dosage or duration)
Study: 32053634
Drug: CC-only resuscitation
Normalized name: CALCIUM 0.8 ORAL TABLET [OnlyCal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-only resuscitation
Study: 36308135
Drug: Basal salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal salt solution plus technique (Group 2 - BSS)
Study: 33947367
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (patient education and physiotherapy)
Study: 33942724
Drug: 1% progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% progesterone gel
Study: 32227554
Drug: GSK2798745 (TRPV4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2798745 (TRPV4 antagonist)
Study: 33059997
Drug: Iodine-125 (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-125 (125I) brachytherapy, prescription dose 144 Gy
Study: 33059997
Drug: Cesium-131 (131Cs)
Normalized name: Cesium
DrugBank: Cesium (DB15392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cesium-131 (131Cs) brachytherapy, prescription dose 115 Gy
Study: 32585017
Drug: Sildenafil, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil, 25 mg, 3 times a day
Study: 34261807
Drug: Genicular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genicular nerve blockade (15 mL 0.25% bupivacaine and 2 mg dexamethasone)
Study: 33834250
Drug: Interviewer knowledge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer knowledge treatment (trained interviewers)
Study: 34017029
Drug: Pulse D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse D therapy (60,000 IUs of vitamin D daily for 8 or 10 days depending on BMI)
Study: 34017029
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (NVD group)
Study: 33208170
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) boost after urgent 3D conformal radiotherapy (3DCRT)
Study: 35379238
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg up to three times daily
Study: 33071273
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise plus leucine supplement (RL)
Study: 34133981
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (amoxicillin 500mg) under fasted conditions
Study: 34133981
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (amoxicillin 500mg) under fed conditions
Study: 34133981
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (amoxicillin 500mg) under fasted conditions
Study: 34133981
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (amoxicillin 500mg) under fed conditions
Study: 32306991
Drug: Ginger tablets
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger tablets (126 tablets for six weeks)
Study: 32306991
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (126 tablets for six weeks)
Study: 35130946
Drug: whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: whole cell pertussis (wP) vaccine
Study: 35130946
Drug: acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: acellular pertussis (aP) vaccine
Study: 32290521
Drug: Leucine-Enriched Essential
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine-Enriched Essential Amino Acids (LEAAs) 4 g thrice daily for four days
Study: 32533536
Drug: ASP4345 (3–150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP4345 (3–150 mg multiple oral doses)
Study: 32533536
Drug: ASP4345 (3–900
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP4345 (3–900 mg single oral doses)
Study: 32533536
Drug: ASP4345 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP4345 (300 mg single oral dose)
Study: 33199274
Drug: Fasinumab 9
Normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasinumab 9 mg subcutaneous every 4 weeks (Q4W)
Study: 33199274
Drug: Fasinumab 9
Normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasinumab 9 mg intravenous every 8 weeks (Q8W)
Study: 33199274
Drug: Fasinumab 6
Normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasinumab 6 mg
Study: 33199274
Drug: Fasinumab 9
Normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasinumab 9 mg intravenous
Study: 34802955
Drug: Classical music
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical music listening (ML)
Study: 34351590
Drug: Oliceridine (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oliceridine (0.1, 0.35, or 0.5 mg)
Study: 34351590
Drug: Pooled data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled data of Morphine
Study: 33356640
Drug: Multimodal exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal exercises integrated with cognitive-behavioural therapy
Study: 34407037
Drug: Heparinized solution
Normalized name: heparin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized solution 100 U/mL (10 mL)
Study: 34407037
Drug: Heparinized solution
Normalized name: heparin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized solution 10 U/mL (20 mL)
Study: 34407037
Drug: Heparinized solution
Normalized name: heparin Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized solution 10 U/mL (30 mL)
Study: 34407037
Drug: Urokinase solution
Normalized name: urokinase Injectable Solution
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urokinase solution
Study: 34407037
Drug: Heparin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin at 10 U/mL
Study: 34964149
Drug: Galantamine 16
Normalized name: galantamine 16 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 16 mg
Study: 32473887
Drug: Drug-Coated Balloons
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-Coated Balloons (DCBs)
Study: 35468321
Drug: Tirzepatide (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (pooled 10 mg and 15 mg)
Study: 36045192
Drug: Checklist-guided medication
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checklist-guided medication review and communication stimulus
Study: 39460685
Drug: Lacosamide (LCM)
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide (LCM) as adjunctive therapy
Study: 35225634
Drug: Twice-weekly sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly sessions of psychotherapy
Study: 35225634
Drug: Weekly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly sessions of psychotherapy
Study: 34493496
Drug: Enhanced therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced therapy (usual care plus measuring skin temperatures at 6-8 plantar sites per foot each day)
Study: 34493496
Drug: Enhanced therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced therapy (with hotspot monitoring and activity reduction)
Study: 34493496
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (podiatric treatment, education, and therapeutic footwear)
Study: 34493496
Drug: Enhanced therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced therapy
Study: 32919816
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (100,000 IU monthly) in participants with 25(OH)D < 50 nmol/L
Study: 32919816
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in participants with 25(OH)D < 50 nmol/L
Study: 34180035
Drug: Fostemsavir (HIV-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir (HIV-1 attachment inhibitor)
Study: 34547260
Drug: Intravenous platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous platelet inhibitors
Study: 34289935
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 2,000 IU daily
Study: 32880504
Drug: Virtual reality-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality-based therapy (VRBT)
Study: 32880504
Drug: Virtual reality-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality-based therapy (VRBT) after 12 weeks
Study: 34579954
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication review with follow-up
Study: 32456525
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) + Nutraceutical Compound (NC) containing Monacolin-K, Berberine Hydrochloride, t-Resveratrol, Quercetin, and Chromium (3 months)
Study: 32456525
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) in monotherapy (3 months)
Study: 32456525
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) + Nutraceutical Compound (NC)
Study: 32456525
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) in monotherapy
Study: 32950246
Drug: NOL-guided fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NOL-guided fentanyl dosing
Study: 32950246
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (fentanyl dosing based on haemodynamics)
Study: 34526307
Drug: H3 diet
Normalized name: Vitamin H3
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H3 diet (n=61) - increase EPA+DHA to 1.5 g/day and maintain linoleic acid at around 7% of energy
Study: 34526307
Drug: H3-L6 diet
Normalized name: Vitamin H3
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H3-L6 diet (n=61) - increase n‐3 EPA+DHA to 1.5 g/day and decrease linoleic acid to ≤1.8% of energy
Study: 34526307
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (n=60) - maintain EPA+DHA at <150 mg/day and linoleic acid at around 7% of energy
Study: 34153451
Drug: Oblong tablet
Normalized name: Cydonia oblonga leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oblong tablet (2.5 × 6 mm)
Study: 34153451
Drug: Syrup (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup (3 ml glucose syrup)
Study: 34153451
Drug: Mini-tablets (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-tablets (2 × 2 mm)
Study: 34389407
Drug: CMT (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMT (combined modality therapy) with 20 Gy IF-RT after chemotherapy
Study: 34389407
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (without IF-RT)
Study: 34389407
Drug: CMT (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMT (combined modality therapy)
Study: 32551097
Drug: Nefopam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (20 mg doses every 8 hours)
Study: 32065485
Drug: Chlorhexidine patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine patches (CHG patches)
Study: 34100788
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal daily workout without MHJB protocol)
Study: 36316682
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual with information to improve lifestyle habits on their own
Study: 34740351
Drug: Maternal counselling
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal counselling intervention (five monthly counselling sessions plus usual care)
Study: 32493372
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (IM) + Patient-Controlled Epidural Anesthesia (PCEA)
Study: 32493372
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (IM)
Study: 32901255
Drug: Tolvaptan 15
Normalized name: tolvaptan 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 15 mg/day
Study: 34895717
Drug: Optiflow THRIVE™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optiflow THRIVE™ at 70 L min‐1 oxygen
Study: 34895717
Drug: Nasal prong
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal prong oxygen at 4 L min‐1
Study: 35246228
Drug: EMDR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR therapy (ten biweekly 90-min sessions)
Study: 33734299
Drug: Intermediate-dose prophylactic
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose prophylactic anticoagulation (enoxaparin, 1 mg/kg daily)
Study: 33734299
Drug: Standard-dose prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose prophylactic anticoagulation (enoxaparin, 40 mg daily)
Study: 33326064
Drug: Rosuvastatin/Ezetimibe (20/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin/Ezetimibe (20/10 mg)
Study: 33820424
Drug: Supreme Drug-Eluting
Normalized name: Supreme
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supreme Drug-Eluting Stents (DES)
Study: 34449295
Drug: 274 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 274 mg/day ADS-5102
Study: 34449295
Drug: 137 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 137 mg/day ADS-5102
Study: 32720916
Drug: Lottery scratchy
Normalized name: ALLERGENIC EXTRACTS DIAGNOSTIC SCRATCH TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lottery scratchy ticket reward for good bowel preparation
Study: 35265981
Drug: Non-vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vitamin K antagonist oral anticoagulant (NOAC)
Study: 34837305
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gluconate mouthwash (15 ml for 1 min)
Study: 33755640
Drug: Ethyl chloride
Normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl chloride topical anesthetic spray
Study: 36007724
Drug: CTgRT (Stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTgRT (Stereotactic Body Radiation Therapy with CT guidance)
Study: 36007724
Drug: MRgRT (Stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRgRT (Stereotactic Body Radiation Therapy with MRI guidance)
Study: 33526485
Drug: Rectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rectal artesunate (10 mg/kg) followed by intravenous artesunate (2.4 mg/kg)
Study: 36876753
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (control)
Study: 35317614
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg once daily for 7 days
Study: 36942060
Drug: Melatonin 6
Normalized name: melatonin 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 6 mg daily for four weeks
Study: 32640882
Drug: Serial 12-lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial 12-lead electrocardiograms once daily for five days
Study: 33491027
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise program (VIVIFRAIL) for 12 weeks, minimum 3 weekly sessions of 45–60 minutes
Study: 33491027
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received physical daily training (yoga, cardio-dance or tai chi)
Study: 32480417
Drug: Lowest VWF:Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest VWF:Ag quartile (0.43-0.92 IU/mL)
Study: 35078765
Drug: SOC-F (fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC-F (fosfomycin at 100 mg/kg two times per day for up to 7 days)
Study: 35078765
Drug: SOC (standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC (standard-of-care antibiotics)
Study: 33482769
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg subcutaneously once every 4 weeks, with loading doses on study days 8 and 15
Study: 34148781
Drug: Cannabis preparations
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis preparations (most commonly cannabidiol)
Study: 32243402
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine combined with western medicine
Study: 32441241
Drug: Methionine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine plus cystine (Met+Cys) intake at 313 mg/day for P1 (2 to 6 weeks)
Study: 32441241
Drug: Methionine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine plus cystine (Met+Cys) intake at 381 mg/day for P2 (8 to 12 weeks)
Study: 32441241
Drug: Methionine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine plus cystine (Met+Cys) intake at 318 mg/day for P3 (14 to 18 weeks)
Study: 32441241
Drug: Methionine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine plus cystine (Met+Cys) requirements for WG: 20 mg/g for P1, 22 mg/g for P2, 27 mg/g for P3
Study: 32441241
Drug: Methionine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine plus cystine (Met+Cys) requirements for maintenance: 214 mg/kgBW0.75 for P1, 53 mg/kgBW0.75 for P2, 30 mg/kgBW0.75 for P3
Study: 32867994
Drug: Dietary lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lead nitrate at 3.20 mg/kg
Study: 32867994
Drug: Dietary lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lead nitrate at 33.20 mg/kg
Study: 32867994
Drug: Dietary lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lead nitrate at 63.20 mg/kg
Study: 32867994
Drug: Dietary lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lead nitrate at 93.20 mg/kg
Study: 36008074
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation (NMES) device, 8-week home-based intervention, footplate stimulation for 30 minutes daily and quadriceps stimulation for 20 minutes, five times a week.
Study: 35708631
Drug: KGR-BG1 (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: KGR-BG1 (1500 mg oral dose containing 1000 mg active component, twice daily for 6 weeks)
Study: 35708631
Drug: Korean Red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean Red Ginseng Extract (1500 mg oral dose containing 1000 mg active component, twice daily for 6 weeks)
Study: 35708631
Drug: Placebo (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1500 mg oral dose, twice daily for 6 weeks)
Study: 32051147
Drug: Low-dose Sinemet
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Sinemet (levodopa plus carbidopa) for 2 weeks
Study: 32051147
Drug: High-dose Sinemet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Sinemet (levodopa plus carbidopa) for 2 weeks
Study: 32564076
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 10 mg/kg daily for 12 months
Study: 35176678
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) twice weekly